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Abstract
Objectives
To compare the long term results of uterine artery embolisation (UAE) with surgery for women with symptomatic uterine fibroids using the REST trial cohort.
Design
A pragmatic, open, multicentre, randomised controlled trial.
Setting
Secondary care. 27 participating UK centres.
Participants 157 women aged 18 and over were randomised (in a 2:1 ratio): 106 to UAE and 51 to surgery (hysterectomy 42, myomectomy 9). Those who had symptomatic fibroid(s) larger than 2 cm were candidates for randomisation. Exclusion criteria included subserosal pedunculated fibroids, recent or ongoing pelvic infection, pregnancy, severe allergy to iodinated contrast media and any contraindication to surgery.
Interventions
Surgical arm included either hysterectomy or myomectomy compared with the UAE arm which was a bilateral uterine artery embolisation.
Main outcome measures
Quality of life at 5 years as assessed by the Medical Outcomes Study 36-item Short Form General Health Survey (SF-36). Secondary measures included complications, adverse events and the need for further intervention. A cost utility analysis was also performed.
Results
There were no significant differences between groups in any of the eight components of the SF-36 scores at 5 years (minimum p = 0.45). For 6 of the 8 components of the 5 SF-36 the 95% confidence intervals exclude a mean difference in excess of 10 points.
Symptom score reduction and patient satisfaction with either treatment was very high with no group difference. Major adverse events rates were similar in both groups (19% embolization and 25% surgery, p=0.40). The intervention rate for treatment failure or complications in the UAE arm increased from 13% at 12 months to 32% at 5 years. In contrast the intervention rate in the surgical arm remained at 4%. Initial cost benefit of UAE over surgery at 12 months was lost due to subsequent interventions, with treatments being cost neutral at 5 years.
Conclusions
UAE is a satisfactory alternative to surgery for women with fibroids. The less invasive nature of UAE, needs to be balanced against the need for re-intervention in a significant minority. The choice should lie with the informed patient.
Trial registration: ISRCTN.org number, ISRCTN23023665.
Funding: Chief Scientist Office (CSO), Edinburgh, Scotland
What is already known on the subject ?
•Uterine artery embolisation is an accepted alternative to surgery for women with fibroids.
•Advantages include a more rapid convalescent period and uterine preservation
•A significant minority require further invasive treatment in the first year for either complications or recurrent and persistent symptoms.
What this study adds ?
•The majority of further interventions following UAE (surgery or repeat UAE) occur beyond the first year of follow up.
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•Further research on UAE should focus on better patient selection and outcomes.The apparent economic advantage of UAE at 2 years is lost at 5 years that has important implications for the health service.
Introduction
Uterine fibroids are a common health problem in pre-menopausal women and treatment is traditionally surgical (hysterectomy or myomectomy 6 The clinical findings show some similarity with our data but this paper does not include an economic analysis
The aim of this study is to provide 5 year clinical and economic outcomes of the REST trial (uterine-artery embolization versus surgery for symptomatic uterine fibroids) cohort and to determine whether the previously published early results are durable. 4 This will allow a more effective comparison of UAE with surgery and provide vital information to doctors, patients and health care providers.
Methodology
Trial Design
Formatted: Highlight
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The REST trial commenced in November 2000 in seven Scottish hospitals but later expanded to include a total of 27 centres, including two in England.
Ethics committee approval was granted by the Multicentre Research Ethics
Committee and local approval granted at every centre. A trial coordinator was appointed to supervise the trial and 4 research nurses covered the 27 sites together with a research fellow in gynaecology.
A randomised parallel group study was carried out. Patients were randomised according to a computer generated (permuted blocks) schedule held by the study coordinator. Randomisation used a 2:1 ratio with twice as many subjects being allocated to the new treatment (UAE). Randomisation was stratified by centre and was done centrally by the trial coordinator once the entry criteria had been confirmed and baseline data submitted. The trial randomised 157 women with symptomatic fibroids to either UAE 106, or surgery 51 (hysterectomy 42, myomectomy 9).
The 12 month results were completed in September 2005 and have been published. 4 The patients were followed annually for a further 4 years, collecting all the original outcome measures, which was funded as a separate grant from the CSO.
Participants
Patients were recruited at the local gynaecology clinics. Women at least 18 years old were eligible if they had one or more fibroids of more than 2cm in diameter that could be adequately imaged using magnetic resonance imaging (MRI) and causing symptoms (such as menorrhagia or bulk symptoms) and were considered by their gynaecologist to justify surgical treatment. Exclusion criteria included a contraindication to MRI, severe allergy to iodinated contrast media, subserosal pedunculated fibroids, recent or ongoing pelvic inflammatory disease and any 8 contraindication to surgery. There was no upper limit on the size or number of fibroids.
Data were collected by a research coordinator using a combination of postal questionnaires and telephone contact. Outcomes were recorded annually after the first 12 months up to 5 years following treatment.
Interventions
Experienced interventional radiologists carried out the embolisation procedure with referral to specialist centres from peripheral units where required. Hysterectomy and myomectomy were carried out at each local centre. The method of hysterectomy and myomectomy was left to the discretion of the operator and was not prescribed.
Similarly the precise technique for embolisation was left to the operator but both uterine arteries had to be embolised and the particle size of the embolic agent standardised at 500-710 microns.
Outcome measures
The primary outcome measure was quality of life (QoL) as assessed at 1 year on the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36) with scores ranging from 0 to 100, higher scores indicating better health-related QoL. The primary outcome measure and all the secondary outcomes were re-evaluated at 5 years (forming the content of this report). Secondary outcomes included the EuroQol-5D questionnaire, an 11-point symptom score, ranging from -5 (markedly worse) to +5 (markedly better), a satisfaction score (measuring whether patients would recommend the procedure to a friend), complications, adverse events and the need for 9 further intervention for treatment failure. Follow up intervals were 1, 6, 12, months and annually thereafter.
Complications and Serious Adverse Events
All complications were graded using the Society of Interventional Radiology (SIR)
classification as shown below. was assessed pre-treatment and up to one year after both UAE and surgery. These results have been published elsewhere. 9 In women of the age of those in this study, further follow up with hormone assessment was unlikely to provide additional useful information.
Sample Size
The original power calculation required a total study size of 200 participants to give 90% power to detect at the 5% significance level a difference of 10 points in the SF-36 score at 12 months (the primary endpoint). This calculation took account of the baseline adjustment and the unbalanced randomisation. It was subsequently agreed to reduce the power to 80%, which required a total sample size of 150 participants. This decision was taken in consultation with the main trial funder, in view of the slow initial recruitment rate.
An independent data monitoring committee reviewed the accumulating results and any SAEs on an on-going basis. They followed the highly conservative 'Peto' 11 approach to guide any recommendation to terminate the trial prematurely. Stopping rules did not need to be implemented.
Statistical methods
Analysis was by intention to treat. The quality of life scales (SF-36 and EuroQol)
were analysed using analysis of covariance to adjust for baseline values. Other comparisons between groups used a two sided Student's t-test for continuous data and were estimated from patient responses to the EuroQol-5D questionnaire using a standard weighting process. 10 The mean costs and QALYs gained were calculated for the overall five-year period. All costs and QALYs were discounted at 3.5% as 12 recommended by NICE. 11 The 95% confidence intervals for the difference in mean costs and QALYs were estimated using bias-corrected and accelerated bootstrap methods. In addition, sensitivity analysis was also carried out on key unit costs by varying one component at a time.
Results
The original trial randomised 157 women to UAE (106) and surgery (51) between 2000 -2004. The groups were well matched at baseline (Table 1) . 1 13/148 patients (9%) had largest fibroid of less than 4cm diameter and 2/148 patients (1%) had largest fibroid of less than 3cm diameter. 2 SF-36 and EuroQol range from 0 (worst possible) to 100 (best possible).
Eight patients (5%) did not receive their allocated treatment (five did not receive UAE and three did not receive surgery). There was one technical failure in the surgical arm with a myomectomy being converted to hysterectomy due to technical difficulties.
Three patients in the UAE arm had a failed procedure due to difficulty identifying or catheterising one or both uterine arteries. Two subsequently underwent a hysterectomy and one had no further treatment. All the hysterectomies and myomectomies were performed through an abdominal incision.
14 The five year follow up study was completed in 2009. Only 10 (10%) (UAE group) and 3 (6%) (surgery group) were lost to 5 year follow up (Figure1). Table 2 . There were no significant differences between groups in any of the components of the QoL measures. For 6 of the 8 components of the SF-36 the 95% confidence intervals exclude a mean difference in excess of 10 Mean SF scores at 5 years post treatment and age matched women in the normal population 16 women who reported that they would recommend their treatment to a friend, was high in both treatment groups (90% in the UAE group and 87% in the surgical group, p=0.56). (Table 2 ). 2 For the differences in quality-of-life scores (on the SF-36 and EuroQol) between the surgical group and the UAE group, the analysis of covariance is adjusted for baseline values, so the differences between the groups are not simple numerical differences.
Negative values indicate higher scores in the UAE group, and positive numbers indicate higher scores in the surgical group. 3 Scores on the Euroqol range from 0 (worst possible) to 100 (best possible) 4 Symptom score (-5 (markedly worse) to +5 (markedly better) 
Major Adverse Events and Complications
A total of 33 major adverse events and major complications were reported over the 5 year period (13 (25%) surgical, 20 (19%) UAE) and rates were similar in both groups 19 (p=0.40). Most of these occurred in the first year with 10 (20%) women in the surgical group and 13 (12%) in the UAE group. Between one to five years 3 (6%) in the surgical group reported a major complication and 7 (7%) in the UAE arm). (Table   3 ). Eleven patients (10%) in the UAE group and one (2%) in the surgical group had a further intervention for further symptoms during the first 12 months of the study, the details of which have been previously reported. 4 At 5 years a further 17 (16%) patients in the UAE group had either a repeat UAE (4) or a hysterectomy (13) . There were no further interventions in the surgical arm beyond 1 year. (Figure 3 ).
The Cumulative Risk for Further Intervention
The cumulative risk for further intervention includes both those for recurrent symptoms and complications/SAEs and is probably more useful information for individual patients to understand. The cumulative risk for further intervention over the entire 5 year period is 32% after UAE and 4% after surgery. (Figure 3 ). Three were delivered by Caesarean section with one post-partum haemorrhage due to an atonic uterus and another due to a morbidly adherent placenta. In a further case, the placenta was described as morbidly adherent but delivery was not associated with excessive blood loss. One intrauterine death of the foetus occurred at 33 weeks. The birth weight of the fetus was above the 90 th centile with no evidence of intrauterine 
Economic Evaluation
During the year 1 to year 5 follow up, the UAE arm of this study was associated with a greater number of further interventions, and subsequent greater resource use and costs compared with the surgery arm (mean costs of £671 compared with £318). This finding is in contrast to that observed in the first 12 months when UAE was associated with substantially lower costs compared with surgery (mean costs of £1727 compared with £2673). 4 As a result, over the period from baseline to five year follow up, UAE 23 no longer has a cost benefit compared with surgery; the total cost associated with UAE was similar to that of surgery (difference of £554). Similarly, there was little difference in QALYs between the UAE group and surgery group for the five year period (difference of -0.02 QALYs). Sensitivity analyses for year one to year five did not alter the results when assumptions were varied around the cost of MRI and US.
Increasing the cost of agent and reducing the cost of inpatient stay showed a slightly higher, now significant, mean difference between the two treatments. (Table 3 ). .09 per scan; and outpatient consultation £99 per visit. The differences in costs between the surgical and UAE group were calculated using a bootstrap method, therefore the difference between the groups are not simple numerical ones. One way sensitivity analysis were preformed on key unit-costs components by varying one measure at a time.
24
Discussion
The initial 12 month results of the REST trial showed no difference in the quality of life gain between surgery and UAE. 4 The 5 year results show this gain to be durable in both groups which achieved levels comparable with normative data from an age matched population. In addition, both treatments are associated with very high patient satisfaction scores of almost 90%. The symptom relief score, which was initially significantly better in the surgical arm at 12 months, continued to improve over the next 4 years in both arms of the study with ultimately no significant difference between groups. This may be related to the higher re-intervention rate (32%) in the UAE arm and possibly a further reduction in uterine and fibroid volume over time.
The re-intervention rate is significantly higher in the UAE group (32%) than the surgical group (4%) at 5 years. For the purpose of this trial re-intervention included all invasive treatments whether for complications, persistent or recurrent symptoms.
Most of the re-intervention is for persistent or recurrent symptoms but we also saw 5 patients who required either hysterectomy (n=3), endometrial ablation (n=1), or D&C (n=1) for complications related to UAE. There were also 5 patients in the UAE arm that either had a technical failure (n=3) or opted to have surgery in spite of being randomised to UAE (n=2). Interestingly the re-intervention rate in the UAE arm increased from 13% at 12 months to 32% at 5 years. In contrast the intervention rate in the surgical arm remained at 4%. This is important new information when counselling patients. We found a similar trend regarding complications with the majority of the surgical arm complications occurring within the first 30 days whereas in the UAE arm most complications occurred beyond the traditional 30 day "surgical window".
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The EMMY trial (hysterectomy vs. UAE) has recently reported a 28.4%
hysterectomy rate for insufficient symptom control in the UAE arm. 6 Our findings concerning the likelihood of re-intervention following UAE are similar to these.
However, re-intervention following surgery was much lower in our study for reasons that are currently unclear.
The HOPEFUL retrospective cohort study reported a further intervention rate of 23% at 4.6 years 12 in the UAE group. The US fibroid registry (n=1916) followed up 1278 (67%) and reported a further intervention rate of 14% at 3 years. 13 In a non randomised study comparing UAE with myomectomy, the further intervention rate was 29% in the UAE arm and 3% after myomectomy. 14 He reported a cumulative re-intervention rate at 5 years, varying from 3% (with complete infarction) to 20% (with <90% infarction). 15 The cause of incomplete infarction is poorly understood but factors such as the type of embolic agent used, embolic end point of the procedure and uterine collateral blood supply from ovarian vessels, are all likely factors.
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Little is known about pregnancy outcomes after UAE and this trial was not set up or powered for this outcome. Of the 10 pregnancies in the UAE arm 4 (40%) resulted in early miscarriage with an additional ectopic pregnancy and one pre-term intra-uterine death. It is difficult to comment on these outcomes although recent publications suggest an increased incidence of spontaneous miscarriage, caesarean section and postpartum haemorrhage after UAE when compared with age-matched women with fibroids. 16 Whilst one woman delivered pre-term, there were no cases of intra-uterine growth retardation or malpresentation, which is reassuring.
There were no cases of premature ovarian failure (i.e. in women under 40 years of age) although gonadotrophins rose to post menopausal levels in a significant number of women over 45 years of age in both groups which is perhaps not surprising since FSH values increase with age. Further research is required in the group of women who wish to maintain their fertility as the possibility of embolic particles causing permanent loss of ovarian function and reserve cannot currently be excluded. A study will be required in women having the procedure prior to the age of 35 if this question is to be answered..
The initial cost benefit of UAE over surgery seen at 12 months was lost at 5 years due to the further intervention rate. The HOPEFUL study showed a similar outcome in cost effectiveness. 17 Limitations of this trial must be acknowledged. The original target number of 200 patients was reduced to 157 owing to difficulty in recruitment. In addition, the number of women undergoing myomectomy was too small to draw any meaningful conclusions.
In conclusion, the improvement in quality of life resulting from either surgery or UAE seen at 1 year was maintained and equal in both groups at 5 years with 91% follow 27 up. UAE is a safe and effective technique for women with symptomatic fibroids who wish to avoid conventional surgery (hysterectomy). Its safety profile (complication and adverse event rates) is similar to surgery, with most of the complications occurring within the first 12 months. Symptomatic relief and satisfaction with treatment are excellent in both groups.
Almost a third of participants in the UAE arm required further invasive treatment.
This resulted in the initial cost benefit at 1 year being lost at 5 years, with both treatments ultimately having a similar cost. The less invasive nature of UAE and its associated more rapid recovery needs to be balanced against the need for further intervention. The choice should lie with the informed patient.
